Education
About Us
Working with TipRanks
Follow Us
Nanologica AB (DE:4YD)
FRANKFURT:4YD
4YD Stock Chart & Stats
€0.04
<€0.01(1.49%)
At close: 4:00 PM EST
€0.04
<€0.01(1.49%)
Day’s Range― - ―
52-Week Range€0.03 - €0.15
Previous CloseN/A
Volume0.00
Average Volume (3M)2.00
Market Cap
€10.98M
Enterprise Value€53.87M
Total Cash (Recent Filing)€3.55M
Total Debt (Recent Filing)€21.68M
Price to Earnings (P/E)―
Beta1.73
Next Earnings
May 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding294,524,100
10 Day Avg. Volume7
30 Day Avg. Volume2
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)3.04
Price to Sales (P/S)3.26
P/FCF Ratio-1.69
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)€7.79M
Bulls Say, Bears Say
Bulls Say
Revenue Growth TractionSustained top-line growth indicates improving commercial traction for Nanologica's nanoparticle platform. Durable revenue expansion from collaborations suggests increasing market acceptance and strengthens the case for recurring milestone and royalty income that can support longer-term R&D and partnerships.
Manageable LeverageRelatively low reported leverage gives the company more financial flexibility versus highly leveraged peers. Manageable debt levels reduce immediate solvency risk, preserving capacity to fund development programs, negotiate partnership terms, or access incremental capital without acute refinancing pressure.
Collaboration/licensing Business ModelA partnership and licensing-led model is capital-light and aligns incentives with pharma partners, offering milestone and royalty upside. This structure spreads development risk, can deliver non-dilutive revenue, and facilitates commercial scale via partner sales forces rather than building expensive in-house commercialization.
Bears Say
Negative Gross Profit And Large Net LossesNegative gross profit and persistent net losses show the core technology has not yet generated sustainable margins. This undermines operating leverage and return metrics, erodes equity over time, and means future growth must translate into meaningful gross-profit recovery to create a durable, self-funding business.
Heavy Cash Burn And Worsening Free Cash FlowDeeply negative operating and free cash flows raise ongoing financing risk and the likelihood of dilution or restrictive financing terms. Persistent cash burn limits runway for R&D or commercialization investment and makes the company dependent on external capital access over the medium term.
Small Operating ScaleA very small headcount constrains internal capacity to manage complex drug-delivery projects, regulatory filings, and larger partnerships. Heavy reliance on partners and contractors increases execution risk and may slow productization, scale-up, and oversight as collaborations move toward commercial stages.
Nanologica AB News
4YD FAQ
What was Nanologica AB’s price range in the past 12 months?
Nanologica AB lowest stock price was €0.03 and its highest was €0.15 in the past 12 months.
What is Nanologica AB’s market cap?
Nanologica AB’s market cap is €10.98M.
When is Nanologica AB’s upcoming earnings report date?
Nanologica AB’s upcoming earnings report date is May 20, 2026 which is in 64 days.
How were Nanologica AB’s earnings last quarter?
Nanologica AB released its earnings results on Feb 26, 2026. The company reported -€0.017 earnings per share for the quarter, missing the consensus estimate of -€0.009 by -€0.008.
Is Nanologica AB overvalued?
According to Wall Street analysts Nanologica AB’s price is currently Overvalued.
Does Nanologica AB pay dividends?
Nanologica AB does not currently pay dividends.
What is Nanologica AB’s EPS estimate?
Nanologica AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Nanologica AB have?
Nanologica AB has 294,524,100 shares outstanding.
What happened to Nanologica AB’s price movement after its last earnings report?
Nanologica AB reported an EPS of -€0.017 in its last earnings report, missing expectations of -€0.009. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Nanologica AB?
Currently, no hedge funds are holding shares in DE:4YD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Nanologica AB
Nanologica AB (publ), a nanotechnology company, develops nanoporous silica for applications in the life science industry. The company offers nanoporous silica particles for drug development and chromatography separation. It provides NLAB Silica, a technology platform for drug delivery; NLAB Spiro, an inhalation platform for pulmonary drug delivery; SVEA (U)HPLC analytical columns; and preparative chromatography. Nanologica AB (publ) was founded in 2004 and is based in Södertälje, Sweden.
Technical Analysis
Alzinova AB
―
Biosergen AB
―
Biovica International AB Class B
―
NextCell Pharma AB
―
Spago Nanomedical AB
―